Venrock Adviser, LLC
Clone Performance
Aug 2023–Aug 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends; a captured split can shorten the simulated window. It tracks 100% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
33 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.9% | $3,294,841,599 |
| Financial Services | 0.1% | $3,210,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RLMD | Relmada Therapeutics, Inc. | +2,000,925 | 6,844,305 | $47,362,590 | |
| XFOR | X4 Pharmaceuticals, Inc | +1,603,728 | 1,934,253 | $9,032,961 | |
| ERAS | Erasca, Inc. | +1,509,000 | 17,891,812 | $327,777,995 | |
| SVRA | Savara Inc | +1,005,568 | 14,745,943 | $90,835,008 | |
| ARTV | Artiva Biotherapeutics, Inc. | +434,027 | 2,043,596 | $19,822,881 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | −5,000,000 | 4,982,124 | $18,682,965 | |
| ELVN | Enliven Therapeutics, Inc. | −1,200,000 | 526,331 | $26,711,298 | |
| SYRE | Spyre Therapeutics, Inc. | −700,000 | 2,985,448 | $265,048,073 | |
| VRDN | Viridian Therapeutics, Inc.\DE | −624,792 | 3,257,917 | $59,847,935 | |
| COGT | Cogent Biosciences, Inc. | −357,834 | 1,642,166 | $63,551,824 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterSold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
Held | 8,493,321 | $1,127,318,496 | 34.18% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 4,148,428 | $394,805,892 | 11.97% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Added | 17,891,812 | $327,777,995 | 9.94% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Reduced | 2,985,448 | $265,048,073 | 8.04% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Held | 1,180,000 | $115,026,400 | 3.49% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Held | 10,346,926 | $101,606,813 | 3.08% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 3,603,595 | $93,729,505 | 2.84% | |
| SVRA |
Savara Inc
Healthcare
|
Added | 14,745,943 | $90,835,008 | 2.75% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Held | 3,220,364 | $71,556,488 | 2.17% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 1,642,166 | $63,551,824 | 1.93% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Reduced | 3,257,917 | $59,847,935 | 1.81% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Held | 3,041,719 | $55,998,046 | 1.70% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Held | 2,173,913 | $48,282,607 | 1.46% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 1,602,034 | $47,804,694 | 1.45% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Added | 6,844,305 | $47,362,590 | 1.44% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Held | 4,319,765 | $46,783,054 | 1.42% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,133,576 | $38,404,368 | 1.16% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Held | 6,434,990 | $37,966,441 | 1.15% | |
| ANL |
Adlai Nortye Ltd.
Healthcare
|
Held | 3,212,731 | $36,946,406 | 1.12% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 526,331 | $26,711,298 | 0.81% | |
| HELP |
Cybin Inc.
Healthcare
|
Held | 3,851,654 | $25,459,432 | 0.77% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 1,379,965 | $25,129,162 | 0.76% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 8,695,652 | $21,304,347 | 0.65% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
Added | 2,043,596 | $19,822,881 | 0.60% | |
| CTMX |
CytomX Therapeutics, Inc.
Healthcare
|
Reduced | 4,982,124 | $18,682,965 | 0.57% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
NEW | 2,751,032 | $17,964,238 | 0.54% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
NEW | 625,000 | $17,106,250 | 0.52% | |
| SRZN |
Surrozen, Inc./DE
Healthcare
|
Held | 632,931 | $16,424,559 | 0.50% | |
| KRRO |
Korro Bio, Inc.
Healthcare
|
Held | 1,009,500 | $13,305,210 | 0.40% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Held | 500,000 | $13,195,000 | 0.40% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Added | 1,934,253 | $9,032,961 | 0.27% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 300,000 | $3,210,000 | 0.10% | |
| INM |
InMed Pharmaceuticals Inc.
Healthcare
|
NEW | 32,685 | $50,661 | 0.00% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.